Cytotoxic effect of menadione and sodium orthovanadate in combination on human glioma cells

Investigational New Drugs

Volumn 30, Issue 4, 2012, Pages 1302-1310

  Delwar, Zahid M ^a   Avramidis, Dimitrios ^a   Follin, Elna ^b   Hua, Yan ^c   Siden, Åke ^a   Cruz, Mabel ^a   Paulsson, Kajsa M ^b,d   Yakisich, Juan Sebastian ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c TIANJIN HUANHU HOSPITAL   (China)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cytotoxicity; DTT. Genistein; Gliomas; Menadione; Proliferation; Sodium orthovanadate

Indexed keywords

DITHIOTHREITOL; GENISTEIN; MENADIONE; PROTEIN TYROSINE KINASE; VANADATE SODIUM;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL ASSAY; CELL KILLING; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENCY; DRUG POTENTIATION; GLIOMA; GLIOMA CELL; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; OXIDATIVE STRESS; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; DITHIOTHREITOL; DRUG SCREENING ASSAYS, ANTITUMOR; GENISTEIN; GLIOMA; HUMANS; PROTECTIVE AGENTS; TIME FACTORS; VANADATES; VITAMIN K 3;

EID: 84866734245     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9680-y     Document Type: Article

References (66)

1. Khan MK, Hunter GK, Vogelbaum M, Suh JH, Chao ST. (2009) Evidence-based adjuvant therapy for gliomas: current concepts and newer developments. Indian J Cancer 46:96-107
2. Deltour I, Johansen C, Auvinen A, Feychting M, Klaeboe L, Schüz J. (2009) Time trends in brain tumor incidence rates in Denmark, Finland, Norway, and Sweden, 1974-2003. J Natl Cancer Inst 101:1721-1724
3. Donelli MG, Zucchetti M, D'Incalci M. (1992) Do anticancer agents reach the tumor target in the human brain? Cancer Chemother Pharmacol 30:251-260
4. Juillerat-Jeanneret L. (2008) The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles? Drug Discov Today 13:1099-1106
5. Laquintana V, Trapani A, Denora N, Wang F, Gallo JM, Trapani G. (2009) New strategies to deliver anticancer drugs to brain tumors. Expert Opin Drug Deliv 6:1017-1032
6. Jiang H, Shang X, Wu H, Huang G, Wang Y, Al-Holou S, Gautam SC, Chopp M. (2010) Combination treatment with resveratrol and sulforaphane induces apoptosis in human U251 glioma cells. Neurochem Res 35:152-161
7. Wu H, Jiang H, Lu D, Xiong Y, Qu C, Zhou D, Mahmood A, Chopp M. (2009) Effect of simvastatin on glioma cell proliferation, migration, and apoptosis. Neurosurgery 65:1087-1096
8. Cruz M, Siden Å, Tasat DR, Yakisich JS. (2010) Are all glioma cells cancer stem cells? J Cancer Sci Ther 2:100-106
9. Laks DR, Visnyei K, Kornblum HI. (2010) Brain tumor stem cells as therapeutic targets in models of glioma. Yonsei Med J 51:633-640
10. Yakisich JS, Ohlsson Lindblom I, Siden A, Cruz MH. (2009) Rapid inhibition of ongoing DNA synthesis in human glioma tissue by genistein. Oncol Rep 22:569-574
11. Matzno S, Yamaguchi Y, Akiyoshi T, Nakabayashi T, Matsuyama K. (2008) An attempt to evaluate the effect of vitamin K3 using as an enhancer of anticancer agents. Biol Pharm Bull 31:1270-1273
12. Chlebowski RT, Dietrich M, Akman S, Block JB. (1985) Vitamin K3 inhibition of malignant murine cell growth and human tumor colony formation. Cancer Treat Rep 69:527-532
13. Akman SA, Doroshow JH, Dietrich MF, Chlebowski RT, Block JS. (1987) Synergistic cytotoxicity between menadione and dicumarol vs. murine leukemia L1210. J Pharmacol Exp Ther 240:486-491
14. Duthie SJ, Grant MH. (1989) The toxicity of menadione and mitozantrone in human liver-derived Hep G2 hepatoma cells. Biochem Pharmacol 38:1247-1255
15. Okayasu H, Ishihara M, Satoh K, Sakagami H. (2001) Cytotoxic activity of vitamins K1, K2 and K3 against human oral tumor cell lines. Anticancer Res 21:2387-2392
16. Tetef M, Margolin K, Ahn C, Akman S, Chow W, Leong L, Morgan RJ Jr, Raschko J, Somlo G, Doroshow JH. (1995) Mitomycin C and menadione for the treatment of lung cancer: a phase II trial. Invest New Drugs 13:157-162
17. Akiyoshi T, Matzno S, Sakai M, Okamura N, Matsuyama K. (2009) The potential of vitamin K3 as an anticancer agent against breast cancer that acts via the mitochondria-related apoptotic pathway. Cancer Chemother Pharmacol 65:143-150
18. Baran I, Ganea C, Scordino A, Musumeci F, Barresi V, Tudisco S, Privitera S, Grasso R, Condorelli DF, Ursu I. (2010) Effects of menadione, hydrogen peroxide, and quercetin on apoptosis and delayed luminescence of human leukemia Jurkat T-cells. Cell Biochem Biophys 58:169-179
19. Oztopçu P, Kabadere S, Mercangoz A, Uyar R. (2004) Comparison of vitamins K1, K2 and K3 effects on growth of rat glioma and human glioblastoma multiforme cells in vitro. Acta Neurol Belg 104:106-110
20. Prasad KN, Edwards-Prasad J, Sakamoto A. (1981) Vitamin K3. (menadione) inhibits the growth of mammalian tumor cells in culture. Life Sci 29:1387-1392
21. Vita MF, Nagachar N, Avramidis D, Delwar ZM, Cruz MH, Siden A, Paulsson KM, Yakisich JS. (2010) Pankiller effect of prolonged exposure to menadione on glioma cells: potentiation by vitamin C. Invest New Drugs, in press
22. Avramidis D, Cruz M, Sidén Å, Tasat DR, Yakisich JS. (2009) Regrowth concentration zero. (RC0) as complementary endpoint parameter to evaluate compound candidates during preclinical drug development for cancer treatment. J Cancer Sci Ther 1:019-024
23. Brière JJ, Schlemmer D, Chretien D, Rustin P. (2004) Quinone analogues regulate mitochondrial substrate competitive oxidation. Biochem Biophys Res Commun 316:1138-1142
24. Floreani M, Carpenedo F. (1992) One- and two-electron reduction of menadione in guinea-pig and rat cardiac tissue. Gen Pharmacol 23:757-762
25. Hu OY, Wu CY, Chan WK, Wu FY, Whang-Peng J. (1996) A pharmacokinetic study with the high-dose anticancer agent menadione in rabbits. Biopharm Drug Dispos 17:493-499
26. Lamson DW, Plaza SM. (2003) The anticancer effects of vitamin K. Altern Med Rev 8:303-318
27. Ham SW, Song JH, Kim HI, Jin S. (2000) Mechanism of cell cycle arrest by menadione. Bull Korean Chem Soc 21:1173-1174
28. Holko P, Ligeza J, Kisielewska J, Kordowiak AM, Klein A. (2008) The effect of vanadyl sulphate. (VOSO4) on autocrine growth of human epithelial cancer cell lines. Pol J Pathol 59:3-8
29. Kordowiak AM, Klein A, Goc A, Dabroś W. (2007) Comparison of the effect of VOSO4, Na3VO4 and NaVO3 on proliferation, viability and morphology of H35-19 rat hepatoma cell line. Pol J Pathol 58:51-57
30. Klein A, Holko P, Ligeza J, Kordowiak AM. (2008) Sodium orthovanadate affects growth of some human epithelial cancer cells. (A549, HTB44, DU145). Folia Biol Krakow 56:115-121
31. Capella LS, Gefé MR, Silva EF, Affonso-Mitidieri O, Lopes AG, Rumjanek VM, Capella MA. (2002) Mechanisms of vanadateinduced cellular toxicity: role of cellular glutathione and NADPH. Arch Biochem Biophys 406:65-72
32. Capella MA, Capella LS, Valente RC, Gefé M, Lopes AG. (2007) Vanadate-induced cell death is dissociated from H2O2 generation. Cell Biol Toxicol 23:413-420
33. Srivastava AK, Mehdi MZ. (2005) Insulino-mimetic and antidiabetic effects of vanadium compounds. Diabet Med 22:2-13
34. Byrne AR, Kosta L. (1978) Vanadium in foods and in human body fluids and tissues. Sci Total Environ 10:17-30
35. Srivastava AK. (2000) Anti-diabetic and toxic effects of vanadium compounds. Mol Cell Biochem 206:177-182
36. Uthus EO, Nielsen FH. (1990) Effect of vanadium, iodine and their interaction on growth, blood variables, liver trace elements and thyroid status indices in rats. Magnes Trace Elem 9:219-226
37. Shafrir E, Spielman S, Nachliel I, Khamaisi M, Bar-On H, Ziv E. (2001) Treatment of diabetes with vanadium salts: general overview and amelioration of nutritionally induced diabetes in the Psammomys obesus gerbil. Diab Metab Res Rev 17:55-66
38. Gordon JA. (1991) Use of vanadate as protein-phosphotyrosine phosphatase inhibitor. Meth Enzymol 201:477-482
39. Abdelmohsen K, Patak P, Von Montfort C, Melchheier I, Sies H, Klotz LO. (2004) Signaling effects of menadione: from tyrosine phosphatase inactivation to connexin phosphorylation. Meth Enzymol 378:258-272
40. Nakayama T, Asami S, Ono S, Miura M, Hayasaka M, Yoshida Y, Toriyama M, Motohashi S, Suzuki T. (2009) Effect of cell differentiation for neuroblastoma by vitamin K analogs. Jpn J Clin Oncol 39:251-259
41. McDonagh B, Sheehan D. (2007) Effect of oxidative stress on protein thiols in the blue mussel Mytilus edulis: proteomic identification of target proteins. Proteomics 7:3395-3403
42. Pani G, Colavitti R, Bedogni B, Anzevino R, Borrello S, Galeotti T. (2000) A redox signaling mechanism for density-dependent inhibition of cell growth. J Biol Chem 275:38891-38899
43. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. (2006) Clonogenic assay of cells in vitro. Nat Protoc 1:2315-2319
44. Sankar A, Thomas DG, Darling JL. (1999) Sensitivity of shortterm cultures derived from human malignant glioma to the anticancer drug temozolomide. Anticancer Drugs 10:179-185
45. Sakai A. (1997) Orthovanadate, an inhibitor of protein tyrosine phosphatases, acts more potently as a promoter than as an initiator in the BALB/3T3 cell transformation. Carcinogenesis 18:1395-1399
46. Cortizo AM, Bruzzone L, Molinuevo S, Etcheverry SB. (2000) A possible role of oxidative stress in the vanadium-induced cytotoxicity in the MC3T3E1 osteoblast and UMR106 osteosarcoma cell lines. Toxicology 147:89-99
47. Navis AC, van den Eijnden M, Schepens JT, Hooft van Huijsduijnen R, Wesseling P, Hendriks WJ. (2010) Protein tyrosine phosphatases in glioma biology. Acta Neuropathol 119:157-175
48. Nutter LM, Cheng AL, Hung HL, Hsieh RK, Ngo EO, Liu TW. (1991) Menadione: spectrum of anticancer activity and effects on nucleotide metabolism in human neoplastic cell lines. Biochem Pharmacol 41:1283-1292
49. Lim D, Morgan RJJ, Akman S, Margolin K, Carr BI, Leong L, Odujinrin O, Doroshow JH. (2005) Phase I trial of menadiol diphosphate. (vitamin K3) in advanced malignancy. Invest New Drugs 23:235-239
50. Öztopcu-Vatan P, Kabadere S. (2007) The effects of menadione on rat glial cell proliferation. J Neurol Sci Turk 24:25-28
51. Hasegawa Y, Morioka M, Hasegawa S, Matsumoto J, Kawano T, Kai Y, Yano S, Fukunaga K, Kuratsu J. (2006) Therapeutic time window and dose dependence of neuroprotective effects of sodium orthovanadate following transient middle cerebral artery occlusion in rats. J Pharmacol Exp Ther 317:875-881
52. Száraz P, Bánhegyi G, Benedetti A. (2010) Altered redox state of luminal pyridine nucleotides facilitates the sensitivity towards oxidative injury and leads to endoplasmic reticulum stress dependent autophagy in HepG2 cells. Int J Biochem Cell Biol 42:157-166
53. Niemczyk E, Majczak A, Hallmann A, Kedzior J, Woźniak M, Wakabayashi T. (2004) A possible involvement of plasma membrane NAD(P)H oxidase in the switch mechanism of the cell death mode from apoptosis to necrosis in menadione-induced cell injury. Acta Biochim Polonica 51:1015-1022
54. Wochna A, Niemczyk E, Kurono C, Masaoka M, Kedzior J, Słomińska E, Lipiński M, Wakabayashi T. (2007) A possible role of oxidative stress in the switch mechanism of the cell death mode from apoptosis to necrosis-studies on rho0 cells. Mitochondrion 7:119-124
55. Gilloteaux J, Jamison JM, Lorimer HE, Jarjoura D, Taper HS, Calderon PB, Neal DR, Summers JL. (2004) Autoschizis: a new form of cell death for human ovarian carcinoma cells following ascorbate:menadione treatment. Nuclear and DNA degradation. Tissue Cell 36:197-209
56. Verrax J, Cadrobbi J, Delvaux M, Jamison JM, Gilloteaux J, Summers JL, Taper HS, Buc Calderon P. (2003) The association of vitamins C and K3 kills cancer cells mainly by autoschizis, a novel form of cell death. Basis for their potential use as coadjuvants in anticancer therapy. Eur J Med Chem 38:451-457
57. Morita A, Yamamoto S, Wang B, Tanaka K, Suzuki N, Aoki S, Ito A, Nanao T, Ohya S, Yoshino M. (2010) Sodium orthovanadate inhibits p53-mediated apoptosis. Cancer Res 70:257-265
58. Morita A, Zhu J, Suzuki N, Enomoto A, Matsumoto Y, Tomita M, Suzuki T, Ohtomo K, Hosoi Y. (2006) Sodium orthovanadate suppresses DNA damage-induced caspase activation and apoptosis by inactivating p53. Cell Death Differ 13:499-511
59. Spinozzi F, Pagliacci MC, Migliorati G, Moraca R, Grignani F, Riccardi C, Nicoletti I. (1994) The natural tyrosine kinase inhibitor genistein produces cell cycle arrest and apoptosis in Jurkat Tleukemia cells. Leuk Res 18:431-439
60. Friso A, Tomanin R, Salvalaio M, Scarpa M. (2010) Genistein reduces glycosaminoglycan levels in a mouse model of mucopolysaccharidosis type II. Br J Pharmacol 159:1082-1091
61. Brem S, Tyler B, Li K, Pradilla G, Legnani F, Caplan J, Brem H. (2007) Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. Cancer Chemother Pharmacol 60:643-650
62. McGirt MJ, Brem H. (2010) Carmustine wafers. (Gliadel) plus concomitant temozolomide therapy after resection of malignant astrocytoma: growing evidence for safety and efficacy. Ann Surg Oncol 17:1729-1731
63. Menei P, Metellus P, Parot-Schinkel E, Loiseau H, Capelle L, Jacquet G, Guyotat J, Neuro-oncology Club of the French Society of Neurosurgery. (2010) Biodegradable carmustine wafers. (Gliadel) alone or in combination with chemoradiotherapy: the French experience. Ann Surg Oncol 17:1740-1746
64. Recinos VR, Tyler BM, Bekelis K, Sunshine SB, Vellimana A, Li KW, Brem H. (2010) Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model. Neurosurgery 66:530-537
65. Depape-Brigger D, Goldman H, Scriver CR, Delvin E, Mamer O. (1977) The in vivo use of dithiothreitol in cystinosis. Pediatr Res 11:124-131
66. Klonne DR, Johnson DR. (1985) Renal cortical mercury distribution following dithiothreitol administration. J Toxicol Environ Health 16:137-145